Report on the Remuneration Policy
DiaSorin, ricavi in calo nel primo semestre. +4% ex Covid
Diasorin, il titolo vola in borsa dopo i conti del primo semestre: utili e ricavi in calo ma sopra le attese - MilanoFinanza News
Results | DiaSorin
DiaSorin | Saluggia
Results | DiaSorin
About us | DiaSorin
DiaSorin Inc. | LinkedIn
DiaSorin - The Diagnostic Specialist
DiaSorin Inc. | DiaSorin
DiaSorin S.p.A. Completes Acquisition of the Focus Diagnostics' Molecular and Immunoassay Product Business from Quest Diagnostics
Annual Financial Report
DiaSorin | Saluggia
Borsa: Milano in calo (-0,45%), cede Diasorin, balza Mps - Notizie - Ansa.it
Italy's DiaSorin sees 60% plunge in COVID-19 revenue next year | Reuters
DiaSorin Italia S.p.A. | DiaSorin
Homepage - DiaSorin Molecular
DiaSorin: Overvalued Italian Healthcare Company (OTCMKTS:DSRLF) | Seeking Alpha
DiaSorin - The Diagnostic Specialist
DiaSorin warns of lower revenue as COVID-related demand fades, ET HealthWorld
 "DiaSorin simplifies diagnostics by implementing a digital solution | Reply")
DiaSorin simplifies diagnostics by implementing a digital solution | Reply
Borsa: Milano frena ancora (-1,1%), pesano Diasorin e Stellantis - Notizie - Ansa.it
Our history | DiaSorin
proudtobeDiaSorin | DiaSorin
DiaSorin to Buy Covid-19 Test-Maker Luminex for $1.8 Billion - Bloomberg
Milan: downside move for DiaSorin - Borsa Italiana
Simplexa® SARS-CoV-2 Variants Direct (RUO) - DiaSorin Molecular
Homepage - DiaSorin Molecular
DiaSorin S.p.A. (DIA) Company Information - Simply Wall St
DiaSorin's LIAISON® SARS-CoV-2 Diagnostic Solutions | DiaSorin
Annual Financial Report
DiaSorin : Taking on board the near-term difficulties -August 16, 2023 at 05:46 am| MarketScreener
DIASORIN S.p.A. REPORT ON THE REMUNERATION POLICY AND FEES PAID 2020
Annual Financial Report
DiaSorin Molecular LLC | LinkedIn
Annual Financial Report
Medical Countermeasures | USA Public Health Security
DiaSorin - The Diagnostic Specialist
DiaSorin Spa Italy - DiaSorin Molecular
DiaSorin - The Diagnostic Specialist
Italian biotech company DiaSorin says its Covid-19 tests can detect omicron variant
DiaSorin's LIAISON® SARS-CoV-2 Diagnostic Solutions | DiaSorin
DiaSorin | LinkedIn
DiaSorin S.p.A. | DiaSorin
DiaSorin to Acquire Focus Diagnostics Unit for $300 Million | Clinical Lab Products
DiaSorin Said to Weigh Deal for Covid-Testing Rival Luminex - Bloomberg
Relazione_CG_Esercizio_31 12 2008_en
DiaSorin | Saluggia
